NEW YORK — Proteomics firm Alamar Biosciences said on Wednesday that it has partnered with Mologic to develop a rapid antigen test for SARS-CoV-2.
Under the terms of the deal, the partners will use Alamar's novel SARS-CoV-2 nucleocapsid protein-targeting antibodies to develop the test. Financial and other terms were not disclosed.
"We are very pleased with the increased sensitivity attainable with Alamar antibodies, especially in view of the speed with which they can be developed," Mologic Cofounder and CSO Paul Davis said in a statement. "We look forward to continuing our collaboration to create the road map for unprecedented speed of response to new pandemic threats of whatever origin."
In mid-2021, UK-based Mologic was acquired by a group of investors led by the Soros Economic Development Fund with support from the Bill & Melinda Gates Foundation. Following the transaction, Mologic was integrated into Global Access Health, a social enterprise aiming to expand access to affordable medical technologies in low- and middle-income countries, and became a nonprofit enterprise.
In September, Fremont, California-based Alamar raised $80 million in private financing.